Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00700947 · ClinicalTrials.gov registry record · Phase 1
Using Beta Blockers to Treat Mitral Regurgitation
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00700947 is a Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 27 participants.
The verdict
NCT00700947, a Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study tests whether beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation.
Interventions
- DRUG Beta-blocker therapy (TOPROL-XL® )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00700947
The ClinicalTrials.gov registry entry for NCT00700947 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Beta-blocker therapy (TOPROL-XL® ) is the first listed.
NCT00700947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00700947 about?
NCT00700947 is a clinical study titled "Using Beta Blockers to Treat Mitral Regurgitation". The purpose of this study tests whether beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation.
What is the current status of trial NCT00700947?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2007-10. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00700947?
The interventions under investigation include: Beta-blocker therapy (TOPROL-XL® ) (DRUG).
Who is sponsoring clinical trial NCT00700947?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.